Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Koreth J et al. – At 1–year the non–relapse mortality was zero, cumulative incidence of relapse/progression was 29%, and overall, progression–free, and event–free survival was 75%, 64%, and 59% respectively. Bortezomib is a promising novel immunomodulatory agent in allogeneic transplantation.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address